Skip to main content
SpringerLink
Log in

Second-line nilotinib for Philadelphia chromosome-positive CML: more effective, less costly

  • Non-clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Funding for the conduct and reporting of the study was provided by Novartis Pharma AG.

Reference

  • Bonifacio M, et al. Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy. PharmacoEconomics-Open : 23 Jul 2021. Available from: URL: https://doi.org/10.1007/s41669-021-00286-3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Second-line nilotinib for Philadelphia chromosome-positive CML: more effective, less costly. PharmacoEcon Outcomes News 884, 27 (2021). https://doi.org/10.1007/s40274-021-7934-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7934-2

Search

Navigation